On January 2, 2018, the Board of Directors of Soleno Therapeutics, Inc. resolved to decrease the size of the Board from ten directors to seven directors, effective as of January 1, 2018, such that the number of Class I directors shall be decreased to two members; the number of Class II directors shall be decreased to one member, and the number of Class III directors shall remain the same at four members, in connection with the resignations of Edgar Engleman, Steve Kirnon, and Steinar Engelsen on December 31, 2017. Following the Resignations, on January 2, 2018, the Board appointed Jim Glasheen (Chair), Mahendra Shah, Stuart Collinson, and Rajen Dalal to serve as members of the Nominating and Corporate Governance Committee of the Board; Mahendra Shah (Chair), Ernest Mario, Bill Harris, and Rajen Dalal to serve as members of the Compensation Committee of the Board; and Bill Harris (Chair), Jim Glasheen, and Stuart Collinson to serve as members of the Audit Committee of the Board.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCRâs mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
SOLENO THERAPEUTICS, INC. 
